Comp.1

**Comp.1** is a preclinical dual-responsive peptide-drug conjugate designed for HPV16-driven cervical cancer. It covalently combines the AI-optimized E6-binding peptide P9, derived from the E6AP interaction sequence, with camptothecin. P9 acts as an intracellular decoy that disrupts the interaction between HPV16 E6 and E6AP, thereby reducing E6-mediated p53 degradation and restoring p53 function; the camptothecin payload contributes DNA topoisomerase I-directed cytotoxic activity. The compound was reported by an academic collaboration led by investigators at Southeast University and China Pharmaceutical University.